1.Rare complication of the Lewis operation | Redkoe oslozhnenie operatsii L’iuisa.
Vinnichenko, A.A., Vinnichenko, I.A., Moskalenko, V.L., Korobeǐnik, V.I. Klinicheskaya Khirurgiya, 1990, (10), pp. 53
2. Experience with gastro- and enterostomy in esophageal obstruction | Opyt gastro- i énterostomii pri neprokhodimosti pishchevoda.
Vinnichenko, A.A., Vinnichenko, I.A., Vataman, V.N. Klinicheskaya Khirurgiya, 1991, (10), pp. 30–32
3. Surgical treatment of thoracic esophageal obstruction of neoplastic genesis | Khirurgicheskoe lechenie neprokhodimosti grudnoi chasti pishchevoda opukholevogo geneza.
Veligotskiǐ, N.N., Florikian, A.K., Teslenko, I.V., …Vinnichenko, I.A., Veligotskiǐ, A.N. Klinicheskaya Khirurgiya, 1999, (8), pp. 11–13
4. Platinum-based chemotherapy plus cetuximab in head and neck cancer
Vermorken, J.B., Mesia, R., Rivera, F., …Amellal, N., Hitt, R. New England Journal of Medicine, 2008, 359(11), pp. 1116–1127
5. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
Pirker, R., Pereira, J.R., Szczesna, A., …Emig, M., Gatzemeier, U. The Lancet, 2009, 373(9674), pp. 1525–1531
6. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: The FLAGS trial
Ajani, J.A., Rodriguez, W., Bodoky, G., …Lang, I., Falcon, S. Journal of Clinical Oncology, 2010, 28(9), pp. 1547–1553
7. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: A subgroup analysis of data from the FLEX phase 3 study
Gatzemeier, U., von Pawel, J., Vynnychenko, I., …O’Byrne, K.J., Pirker, R. The Lancet Oncology, 2011, 12(1), pp. 30–37
8. [Spermatogenic function under the influence of heavy metal salts and its correction by preparation Tivortin].
Romaniuk, A.M., Sauliak, S.V., Moskalenko, R.A., Moskalenko, I.V. Likars’ka sprava / Ministerstvo okhorony zdorov’ia Ukraïny, 2012, (1-2), pp. 123–128
9. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: Final results of a phase III trial
Socinski, M.A., Bondarenko, I., Karaseva, N.A., …Iglesias, J.L., Renschler, M.F. Journal of Clinical Oncology, 2012, 30(17), pp. 2055–2062
10. Prognostic factors in patients with advanced non-small cell lung cancer: Data from the phase III FLEX study
Pirker, R., Pereira, J.R., Szczesna, A., …O’Byrne, K.J., Gatzemeier, U. Lung Cancer, 2012, 77(2), pp. 376–382
11. International, randomized, placebo-controlled, double-blindphase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1
Scagliotti, G.V., Vynnychenko, I., Park, K., …Galimi, F., Spigel, D.R. Journal of Clinical Oncology, 2012, 30(23), pp. 2829–2836
12. Medical discourse in pathological anatomy.
Moskalenko, R., Tatsenko, N., Romanyuk, A., Perelomova, O., Moskalenko, Y. Georgian medical news, 2012, (206), pp. 63–66
13. [Vascular-parenchymal ratio of testes under correction of exposure to combinations of heavy metals salts].
Romaniuk, A.M., Moskalenko, I.V., Sauliak, S.V., Bonchev, S.D., Moskalenko, R.A. Likars’ka sprava / Ministerstvo okhorony zdorov’ia Ukraïny, 2013, (4), pp. 122–127
14. Motesanib plus carboplatin/paclitaxel in patients with advanced squamous non-small-cell lung cancer results from the randomized controlled MONET1 study
Novello, S., Scagliotti, G.V., Sydorenko, O., …Hei, Y.-J., Spigel, D.R. Journal of Thoracic Oncology, 2014, 9(8), pp. 1154–1161
15. An open-label, multicenter, randomized phase Ib/II study of eribulin mesylate administered in combination with pemetrexed versus pemetrexed alone as second-line therapy in patients with advanced nonsquamous non-small-cell lung cancer
Waller, C.F., Vynnychenko, I., Bondarenko, I., …Shelton, M.J., Dave, H. Clinical Lung Cancer, 2015, 16(2), pp. 92–99
16. Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS)
Bodoky, G., Scheulen, M.E., Rivera, F., …Cascinu, S., Ajani, J.A. Journal of Gastrointestinal Cancer, 2015, 46(2), pp. 109–117
17. Гормонально-генетичний скринінг у хворих за виразкової гастродуоденальної кровотечі / Дужий І. Д., Романюк А. М., Линдін М. С., Шевченко Ю.Ю. // Клінічна хірургія. – Київ: ТОВ «Ліга – Інформ», 2015. – № 11 – С. 24-27.
18. Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: A randomized clinical trial
Rugo, H.S., Barve, A., Waller, C.F., …Yanez Ruiz, E.P., Pennella, E. JAMA – Journal of the American Medical Association, 2017, 317(1), pp. 37–47
19. The features of morphological changes in the urinary bladder under combined effect of heavy metal salts
Romaniuk, A., Sikora, V., Lyndin, M., …Gyryavenko, N., Korobchanska, A. Interventional Medicine and Applied Science, 2017, 9(2), pp. 105–111
20. Anatomical and morphological aspects of papillae, epithelium, muscles, and glands of rats’ tongue: Light, scanning, and transmission electron microscopic study
Davydova, L., Tkach, G., Tymoshenko, A., …Maksymova, O., Suchonos, O. Interventional Medicine and Applied Science, 2017, 9(3), pp. 168–177
21. Primary multiple tumor with affection of the thyroid gland, uterus, urinary bladder, mammary gland and other organs
Romaniuk, А., Lyndin, M., Smiyanov, V., …Sikora, V., Gladchenko, O. Pathology Research and Practice, 2017, 213(5), pp. 574–579
22. 12 years of fighting liposarcoma: a case report
Kononenko, M., Vynnychenko, I., Moskalenko, Y., Vynnychenko, O. Wiadomosci lekarskie (Warsaw, Poland : 1960), 2017, 70(5), pp. 995–997
23. Eye retinal changes under the influence of chromium ions
Kuzenko, Y.V., Kuzenko, O.V., Dyomin, Y.A. Oftalmologicheskii Zhurnal, 2018, (1), pp. 67–73
24. Ecological causality of the central serous chorioretinopathy incidence in the Sumy region
Kuzenko, O.V., Dyomin, Yu.A., Litvinova, L.V., Kuzenko, E.V. Oftalmologicheskii Zhurnal, 2018, (3), pp. 63–67
25. Effect of heavy metals on the readaptive processes in the urinary bladder
Romaniuk, A., Sikora, V., Lуndіna, Y., …Piddubnyi, A., Miroshnichenko, M. Bangladesh Journal of Medical Science, 2019, 18(1), pp. 100–106
26. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
Rini, B.I., Plimack, E.R., Stus, V., …Atkins, M.B., Powles, T. New England Journal of Medicine, 2019, 380(12), pp. 1116–1127
27. Prostate cancer with intraluminal inclusions: The association of the immunophenotype with grade score
Pidddubnyi, A., Romaniuk, A., Radomychelski, I.-M., Moskalenko, Y., Moskalenko, R.A. Iranian Journal of Pathology, 2019, 14(3), pp. 212–222
28. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Mok, T.S.K., Wu, Y.-L., Kudaba, I., …Nguyen, T.Q., Pham, X.D. The Lancet, 2019, 393(10183), pp. 1819–1830
29. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Paz-Ares, L., Dvorkin, M., Chen, Y., …Sumey, C., Williamson, M. The Lancet, 2019, 394(10212), pp. 1929–1939
30. Morphological Characteristics and Correction of Long Tubular Bone Regeneration under Chronic Hyperglycemia Influence Dudchenko, Y.S., Maksymova, O.S., Pikaliuk, V.S., …Kyptenko, L.I., Tkach, G.F. Analytical Cellular Pathology, 2020, 2020, 5472841
31. Vynnychenko I.O., Pryvalova A.О., Vynnychenko O.I., Lуndіn M.S., Sikora V.V., Romaniuk A.M. (2020). PIK3CA-mutant circulating tumor DNA in patients with breast cancer. Azerbaijan Medical Journal, 3, 79-88. ISSN 0005-2523. https://doi.org/10.34921/amj.2020.3.010
32. Case report of giant nonmetastatic gastrointestinal solid tumor without clinical manifestations in a middle-aged male patient
Vynnychenko, I., Kononenko, M., Smorodska, O., …Lyndin, M., Romaniuk, A. Novosti Khirurgii, 2020, 28(5), pp. 597–602
33. PIK3CA-Mutant circulating tumor dna in patients with breast cancer | SÜd vƆzİsİ xƆrÇƆngİ olan xƆstƆlƆrdƆ mutant pik3ka ⇓ sİrkulyasİya edƆn ŞİŞ dnt-si
Vynnychenko, I.O., Pryvalova, A.О., Vynnychenko, O.I., …Sikora, V.V., Romaniuk, A.M. Azerbaijan Medical Journal, 2020, (3), pp. 79–88
34. Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults with Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial
Blayney, D.W., Zhang, Q., Feng, J., …Huang, L., Shi, Y.-K. JAMA Oncology, 2020, 6(11), e204429
35. Case report of giant nonmetastatic gastrointestinal solid tumor without clinical manifestations in a middle-aged male patient
Vynnychenko, I., Kononenko, M., Smorodska, O., …Lyndin, M., Romaniuk, A. Novosti Khirurgii, 2020, 28(5), pp. 597–602
36. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study
Ferris, R.L., Haddad, R., Even, C., …Fayette, J., Licitra, L. Annals of Oncology, 2020, 31(7), pp. 942–950
37. Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial
Jotte, R., Cappuzzo, F., Vynnychenko, I., …Sandler, A., Socinski, M.A.Journal of Thoracic Oncology, 2020, 15(8), pp. 1351–1360
38. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
Powles, T., Plimack, E.R., Soulières, D., …Atkins, M.B., Rini, B.I. The Lancet Oncology, 2020, 21(12), pp. 1563–1573
39. Morphological and Crystal-Chemical Features of Macro- And Microcalcifications of Human Aorta
Radomychelski, I.-M., Piddubnyi, A., Danilchenko, S., …Moskalenko, Y., Moskalenko, R. Microscopy and Microanalysis, 2021
40. Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
Goldman, J.W., Dvorkin, M., Chen, Y., …Wang, K., Chen, Z. The Lancet Oncology, 2021, 22(1), pp. 51–65
41. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma
Sahin, U., Türeci, Ö., Manikhas, G., …Schuler, M., Al-Batran, S.-E. Annals of Oncology, 2021, 32(5), pp. 609–619
42. MODERN VECTOR in TREATMENT of PATIENTS with LUNG CANCER: TYROSINE KINASE INHIBITORS in EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS (literature review) | Сучасний вектор у лікуванні пацієнтів, хворих на рак легенів: інгібітори тирозин кінази при EGFR мутаціях (огляд літератури)
Smorodska, O.M., Moskalenko, Yu.V., Vynnychenko, I.O., Vynnychenko, O.I., Kostuchenko, V.V. Medicni Perspektivi, 2021, 26(2), pp. 4–11
43. Investigating the protective capacity of polymethylsiloxane polyhydrate against chromium (VI)-induced neurotoxicity of the rat optic nerve
Kuzenko, O.V., Dyomin, Y.A., Kuzenko, E.V. Oftalmologicheskii Zhurnal, 2021, 90(1), pp. 62–69
44. Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer
Rugo, H.S., Pennella, E.J., Gopalakrishnan, U., …Fuentes-Alburo, A., Waller, C.F. Breast Cancer Research and Treatment, 2021, 188(2), pp. 369–377
45. Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial
Rugo, H.S., Pennella, E.J., Gopalakrishnan, U., …Barve, A., Waller, C.F. Breast, 2021, 58, pp. 18–26
46. Intestinal microbiota in Alzheimer’s disease / Т. Ivakhniuk, Yu. Ivakhniuk // Georgian Medical News. – № 4 (313). – 2021. – Р. 94-98
47. Standardization Issues of Test Methods for Engineering Nanomaterials / K. Dyadyura, L. Hrebenyk, Т. Ivakhniuk, Yu. Ivakhniuk, L. Sukhodub // Abstract book 2 nd Grabchenko’s internationalconference on advanced manufacturing processes – InterPartner, LNME – 2021. – P. 797-805
Scopus Author ID: https://www.scopus.com/authid/detail.uri?authorId=24781268000
h-index: 16
ORCID ID: https://orcid.org/0000-0002-2339-6509
1.Rare complication of the Lewis operation | Redkoe oslozhnenie operatsii L’iuisa.
Vinnichenko, A.A., Vinnichenko, I.A., Moskalenko, V.L., Korobeǐnik, V.I.
Klinicheskaya Khirurgiya, 1990, (10), pp. 53
2. Experience with gastro- and enterostomy in esophageal obstruction | Opyt gastro- i énterostomii pri neprokhodimosti pishchevoda.
Vinnichenko, A.A., Vinnichenko, I.A., Vataman, V.N.
Klinicheskaya Khirurgiya, 1991, (10), pp. 30–32
3. Surgical treatment of thoracic esophageal obstruction of neoplastic genesis | Khirurgicheskoe lechenie neprokhodimosti grudnoi chasti pishchevoda opukholevogo geneza.
Veligotskiǐ, N.N., Florikian, A.K., Teslenko, I.V., …Vinnichenko, I.A., Veligotskiǐ, A.N.
Klinicheskaya Khirurgiya, 1999, (8), pp. 11–13
4. Platinum-based chemotherapy plus cetuximab in head and neck cancer
Vermorken, J.B., Mesia, R., Rivera, F., …Amellal, N., Hitt, R.
New England Journal of Medicine, 2008, 359(11), pp. 1116–1127
5. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
Pirker, R., Pereira, J.R., Szczesna, A., …Emig, M., Gatzemeier, U.
The Lancet, 2009, 373(9674), pp. 1525–1531
6. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: The FLAGS trial
Ajani, J.A., Rodriguez, W., Bodoky, G., …Lang, I., Falcon, S.
Journal of Clinical Oncology, 2010, 28(9), pp. 1547–1553
7. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: A subgroup analysis of data from the FLEX phase 3 study
Gatzemeier, U., von Pawel, J., Vynnychenko, I., …O’Byrne, K.J., Pirker, R.
The Lancet Oncology, 2011, 12(1), pp. 30–37
8. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: Final results of a phase III trial
Socinski, M.A., Bondarenko, I., Karaseva, N.A., …Iglesias, J.L., Renschler, M.F.
Journal of Clinical Oncology, 2012, 30(17), pp. 2055–2062
9. Prognostic factors in patients with advanced non-small cell lung cancer: Data from the phase III FLEX study
Pirker, R., Pereira, J.R., Szczesna, A., …O’Byrne, K.J., Gatzemeier, U.
Lung Cancer, 2012, 77(2), pp. 376–382
10. International, randomized, placebo-controlled, double-blindphase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1
Scagliotti, G.V., Vynnychenko, I., Park, K., …Galimi, F., Spigel, D.R.
Journal of Clinical Oncology, 2012, 30(23), pp. 2829–2836
11. Motesanib plus carboplatin/paclitaxel in patients with advanced squamous non-small-cell lung cancer results from the randomized controlled MONET1 study
Novello, S., Scagliotti, G.V., Sydorenko, O., …Hei, Y.-J., Spigel, D.R.
Journal of Thoracic Oncology, 2014, 9(8), pp. 1154–1161
12. An open-label, multicenter, randomized phase Ib/II study of eribulin mesylate administered in combination with pemetrexed versus pemetrexed alone as second-line therapy in patients with advanced nonsquamous non-small-cell lung cancer
Waller, C.F., Vynnychenko, I., Bondarenko, I., …Shelton, M.J., Dave, H.
Clinical Lung Cancer, 2015, 16(2), pp. 92–99
13. Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS)
Bodoky, G., Scheulen, M.E., Rivera, F., …Cascinu, S., Ajani, J.A.
Journal of Gastrointestinal Cancer, 2015, 46(2), pp. 109–117
14. 12 years of fighting liposarcoma: a case report
Kononenko, M., Vynnychenko, I., Moskalenko, Y., Vynnychenko, O.
Wiadomosci lekarskie (Warsaw, Poland : 1960), 2017, 70(5), pp. 995–997
15. Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: A randomized clinical trial
Rugo, H.S., Barve, A., Waller, C.F., …Yanez Ruiz, E.P., Pennella, E.
JAMA – Journal of the American Medical Association, 2017, 317(1), pp. 37–47
16. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
Rini, B.I., Plimack, E.R., Stus, V., …Atkins, M.B., Powles, T.
New England Journal of Medicine, 2019, 380(12), pp. 1116–1127
17. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Mok, T.S.K., Wu, Y.-L., Kudaba, I., …Nguyen, T.Q., Pham, X.D.
The Lancet, 2019, 393(10183), pp. 1819–1830
18. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Paz-Ares, L., Dvorkin, M., Chen, Y., …Sumey, C., Williamson, M.
The Lancet, 2019, 394(10212), pp. 1929–1939
19. Case report of giant nonmetastatic gastrointestinal solid tumor without clinical manifestations in a middle-aged male patient
Vynnychenko, I., Kononenko, M., Smorodska, O., …Lyndin, M., Romaniuk, A.
Novosti Khirurgii, 2020, 28(5), pp. 597–602
20. PIK3CA-Mutant circulating tumor dna in patients with breast cancer | SÜd vƆzİsİ xƆrÇƆngİ olan xƆstƆlƆrdƆ mutant pik3ka ⇓ sİrkulyasİya edƆn ŞİŞ dnt-si
Vynnychenko, I.O., Pryvalova, A.О., Vynnychenko, O.I., …Sikora, V.V., Romaniuk, A.M.
Azerbaijan Medical Journal, 2020, (3), pp. 79–88
21. Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults with Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial
Blayney, D.W., Zhang, Q., Feng, J., …Huang, L., Shi, Y.-K.
JAMA Oncology, 2020, 6(11), e204429
22. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study
Ferris, R.L., Haddad, R., Even, C., …Fayette, J., Licitra, L.
Annals of Oncology, 2020, 31(7), pp. 942–950
23. Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial
Jotte, R., Cappuzzo, F., Vynnychenko, I., …Sandler, A., Socinski, M.A.
Journal of Thoracic Oncology, 2020, 15(8), pp. 1351–1360
24. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
Powles, T., Plimack, E.R., Soulières, D., …Atkins, M.B., Rini, B.I.
The Lancet Oncology, 2020, 21(12), pp. 1563–1573
25. Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
Goldman, J.W., Dvorkin, M., Chen, Y., …Wang, K., Chen, Z.
The Lancet Oncology, 2021, 22(1), pp. 51–65
26. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma
Sahin, U., Türeci, Ö., Manikhas, G., …Schuler, M., Al-Batran, S.-E.
Annals of Oncology, 2021, 32(5), pp. 609–619
27. MODERN VECTOR in TREATMENT of PATIENTS with LUNG CANCER: TYROSINE KINASE INHIBITORS in EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS (literature review) | Сучасний вектор у лікуванні пацієнтів, хворих на рак легенів: інгібітори тирозин кінази при EGFR мутаціях (огляд літератури)
Smorodska, O.M., Moskalenko, Yu.V., Vynnychenko, I.O., Vynnychenko, O.I., Kostuchenko, V.V.
Medicni Perspektivi, 2021, 26(2), pp. 4–11
28. Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer
Rugo, H.S., Pennella, E.J., Gopalakrishnan, U., …Fuentes-Alburo, A., Waller, C.F.
Breast Cancer Research and Treatment, 2021, 188(2), pp. 369–377
29. Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial
Rugo, H.S., Pennella, E.J., Gopalakrishnan, U., …Barve, A., Waller, C.F.
Breast, 2021, 58, pp. 18–26
30 Moskalenko Y, Kurochkin A, Vynnychenko I, Kravets O, Piddubnyi A, Moskalenko R, Potapov O. Toluidine blue for the detection of sentinel lymph nodes in patients with thyroid cancer. Contemp Oncol (Pozn). 2022;26(4):259-267. doi: 10.5114/wo.2022.124585. Epub 2022 Dec 30. PMID: 36816393; PMCID: PMC9933357.
31. Shah, M. A., Udrea, A. A., Bondarenko, I., Mansoor, W., Sánchez, R. G., Sarosiek, T., … & Ajani, J. A. (2022). Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies. Cancers, 14(5), 1168.
32. Bedke, J., Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Waddell, T., … & Powles, T. (2022). Health-related quality of life analysis from KEYNOTE-426: pembrolizumab plus axitinib versus sunitinib for advanced renal cell carcinoma. European Urology, 82(4), 427-439.
33. de Castro Jr, G., Rizvi, N. A., Schmid, P., Syrigos, K., Martin, C., Yamamoto, N., … & NEPTUNE Investigators. (2023). NEPTUNE: phase 3 study of first-line Durvalumab plus tremelimumab in patients with metastatic NSCLC. Journal of Thoracic Oncology, 18(1), 106-119.
34. Psyrri, A., Fayette, J., Harrington, K., Gillison, M., Ahn, M. J., Takahashi, S., … & KESTREL Investigators. (2023). Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study. Annals of Oncology, 34(3), 262-274.
35. Ren, S., Feng, J., Ma, S., Chen, H., Ma, Z., Huang, C., … & Zhou, C. (2023). KEYNOTE‐033: randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD‐L1‐positive, advanced NSCLC. International Journal of Cancer, 153(3), 623-634.
36. Plimack, E. R., Powles, T., Stus, V., Gafanov, R., Nosov, D., Waddell, T., … & Rini, B. I. (2023). Pembrolizumab Plus Axitinib Versus Sunitinib as First-Line Treatment of Advanced Renal Cell Carcinoma: 43-Month Follow-up of the Phase 3 KEYNOTE-426 Study. European Urology, 84(5), 449-454.
37. Plimack, E. R., Powles, T., Stus, V., Gafanov, R., Nosov, D., Waddell, T., … & Rini, B. I. (2023). Corrigendum to” Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study”[Eur. (2023)]. European urology, 84(5), e123-e124.
38. Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study” [Eur. Urol. (2023)] Primack, Elizabeth R. et al. European Urology, Volume 84, Issue 5, e123 – e124
Scopus Author ID: https://www.scopus.com/authid/detail.uri?authorId= 57193309806
h-index: 1
ORCID ID: https://orcid.org/0000-0002-5398-0298
Research ID: ABG-1458-2020
Google Scholar: https://scholar.google.com.ua/citations?hl=uk&user=8tetJHcAAAAJ
h-index: 2
Research Gate: https://www.researchgate.net/profile/Yuliia-Moskalenko-2
1. Medical discourse in pathological anatomy.
Moskalenko, R., Tatsenko, N., Romanyuk, A., Perelomova, O., Moskalenko, Y.
Georgian medical news, 2012, (206), pp. 63–66
2. [Spermatogenic function under the influence of heavy metal salts and its correction by preparation Tivortin].
Romaniuk, A.M., Sauliak, S.V., Moskalenko, R.A., Moskalenko, I.V.
Likars’ka sprava / Ministerstvo okhorony zdorov’ia Ukraïny, 2012, (1-2), pp. 123–128
3. [Vascular-parenchymal ratio of testes under correction of exposure to combinations of heavy metals salts].
Romaniuk, A.M., Moskalenko, I.V., Sauliak, S.V., Bonchev, S.D., Moskalenko, R.A.
Likars’ka sprava / Ministerstvo okhorony zdorov’ia Ukraïny, 2013, (4), pp. 122–127
4. 12 years of fighting liposarcoma: a case report
Kononenko, M., Vynnychenko, I., Moskalenko, Y., Vynnychenko, O.
Wiadomosci lekarskie (Warsaw, Poland : 1960), 2017, 70(5), pp. 995–997
5. Primary multiple tumor with affection of the thyroid gland, uterus, urinary bladder, mammary gland and other organs
Romaniuk, А., Lyndin, M., Smiyanov, V., …Sikora, V., Gladchenko, O.
Pathology Research and Practice, 2017, 213(5), pp. 574–579
6. Prostate cancer with intraluminal inclusions: The association of the immunophenotype with grade score
Pidddubnyi, A., Romaniuk, A., Radomychelski, I.-M., Moskalenko, Y., Moskalenko, R.A.
Iranian Journal of Pathology, 2019, 14(3), pp. 212–222
7. Case report of giant nonmetastatic gastrointestinal solid tumor without clinical manifestations in a middle-aged male patient
Vynnychenko, I., Kononenko, M., Smorodska, O., …Lyndin, M., Romaniuk, A.
Novosti Khirurgii, 2020, 28(5), pp. 597–602
8. Morphological and Crystal-Chemical Features of Macro- And Microcalcifications of Human Aorta
Radomychelski, I.-M., Piddubnyi, A., Danilchenko, S., …Moskalenko, Y., Moskalenko, R.
Microscopy and Microanalysis, 2021
9. Smorodska O, Moskalenko Y, Vynnychenko I, Vynnychenko O, Kostuchenko V. Modern vector in treatment of patients with lung cancer: tyrosine kinase inhibitors in epidermal growth factor receptor mutations (literature review). perspekt. [Internet]. 2021Jun.18 [cited 2021Sep.20];26(2):4-11. Available from: http://journals.uran.ua/index.php/2307-0404/article/view/234379
10. Moskalenko Y, Smorodska O, Deineka V, Kravets O, Moskalenko R. Prognostic factors for recurrence in patients with surgically resected non-small cell lung cancer. Contemp Oncol (Pozn). 2022;26(3):239-246. doi: 10.5114/wo.2022.120638. Epub 2022 Oct 24. PMID: 36381667; PMCID: PMC9641628.
11. Moskalenko Y, Kurochkin A, Vynnychenko I, Kravets O, Piddubnyi A, Moskalenko R, Potapov O. Toluidine blue for the detection of sentinel lymph nodes in patients with thyroid cancer. Contemp Oncol (Pozn). 2022;26(4):259-267. doi: 10.5114/wo.2022.124585. Epub 2022 Dec 30. PMID: 36816393; PMCID: PMC9933357.
12. Piddubnyi, A., Kolomiiets, O., Danilchenko, S., Stepanenko, A., Moskalenko, Y., & Moskalenko, R. (2023). The Prospects of Using Structural Phase Analysis of Microcalcifications in Breast Cancer Diagnostics. Diagnostics, 13(4), 737.
13. Kononenko M, Duzhiy I, Moskalenko Y. TARGETED THERAPY OF ANAPLASTIC THYROID CANCER. East. Ukr. Med. J. [Internet]. 2023Jun.18 [cited 2024Sep.14];11(2):113-20.
14. Duzhiy I, Kononenko M, Moskalenko Y, Zhukova K. PAPILLARY CARCINOMA OF THE THYROGLOSSAL DUCT CYST: A CASE REPORT. East. Ukr. Med. J. [Internet]. 2023Jun.18 [cited 2024Sep.14];11(2):121-6.
15. Moskalenko Y, Vynnychenko O, Sulaieva O, Moskalenko R. THE ROLE OF NEXT-GENERATION SEQUENCING IN LUNG CANCER DIAGNOSIS. East. Ukr. Med. J. [Internet]. 2023Sep.30 [cited 2024Sep.14];11(3):214-23.
16. Moskalenko, Y. (2024). Biological mechanisms of resistance to immune checkpoint inhibitors and overcoming this resistance: Challenges in medical oncology. Regulatory Mechanisms in Biosystems, 15(1), 83-91. https://doi.org/10.15421/022412
Scopus Author ID: 57720919100
h-index: 0
ORCID ID: https://orcid.org/0000-0002-9577-0272
Google Scholar:https://scholar.google.com/citations?view_op=list_works&hl=uk&user=ouTGJgcAAAAJ
Research Gate:https://www.researchgate.net/profile/Kovchun-Viktor
Kovchun, A., Kovchun, V., Kachkovska, V., Prystupa, L. (2023). The role of Low-Dose CT scan in the early diagnosis of malignant neoplasms of different localization. European Respiratory Journal, Sep 2023, 62 (suppl 67) PA5348; DOI: 10.1183/13993003.congress-2023.
Scopus Author ID: https://www.scopus.com/authid/detail.uri?authorId=57219858916
h-index: 2
ORCID ID: https://orcid.org/0000-0003-4021-2334
1. Primary multiple tumor with affection of the thyroid gland, uterus, urinary bladder, mammary gland and other organs
Romaniuk, А., Lyndin, M., Smiyanov, V., …Sikora, V., Gladchenko, O.
Pathology Research and Practice, 2017, 213(5), pp. 574–579
2. The features of morphological changes in the urinary bladder under combined effect of heavy metal salts
Romaniuk, A., Sikora, V., Lyndin, M., …Gyryavenko, N., Korobchanska, A.
Interventional Medicine and Applied Science, 2017, 9(2), pp. 105–111
3. Effect of heavy metals on the readaptive processes in the urinary bladder
Romaniuk, A., Sikora, V., Lуndіna, Y., …Piddubnyi, A., Miroshnichenko, M.
Bangladesh Journal of Medical Science, 2019, 18(1), pp. 100–106
4. Liubchak, V. V., Khomenko, L. M., Kovalishyn, M. P., Ilina, V. V., Babar, T. V., & Sikora, V. V. (2021). New marketing tools in the blood service to optimize quality management.
5. MEDICAL AND ECONOMIC ANALYSIS OF THE CHOICE OF THERAPEUTIC PLASMAPHERESIS METHOD TO OPTIMIZE THE TRANSFUSION CARE QUALITY Liubchak, V.V., Khomenko, L.M., Kovalishyn, M.P., Sikora, V.V., Babar, T.V. Wiadomosci lekarskie (Warsaw, Poland : 1960)This link is disabled., 2021, 74(10), pp. 2466–2470
6. Heavy metals effect on the rat uterus and effictiveness of vitamin E treatment / K. Sikora, M. Lyndin, V. Sikora [et al.] // Jordan journal of biological sciences. – 2023. ─ Vol. 16, № 3. – P. 455─465.
